Trinity Biotech, the Irish biotechnology company which has been listed on Nasdaq for the past three years, has reported an impressive set of results for the first half of 1997, with net profits more than doubling from $450,208 to $1.1 million (£784,481). Turnover in the first half rose from $7.2 million to just over $11 million while net cash at the end of the half-year was over $5 million.

Trinity is looking at the possibility of taking a secondary listing on the Irish stock market, building on the institutional interest in technology shares that has built up as a result of companies like CBT and Iona. Trinity shares currently trade at around $2 on Nasdaq, giving the Irish company a market capitalisation of around $49 million.